Researchers from CNRS and the Université d'Orléans presented the discovery of novel inhibitors of LIM kinases (LIMKs) as potential therapeutic candidates for the treatment of osteosarcoma (OS).
OS Therapies LLC, the developer of a listeria-based cancer vaccine to prevent metastasis and increase overall survival in young people with osteosarcoma, has closed on a $6 million series A financing led by Noble Capital Markets and Tichenor Ventures. The funds will help the company advance its lead candidate, OST-HER2, into a phase IIb trial this year with hopes of a potential FDA filing by in 2022.
